tiprankstipranks
Advertisement
Advertisement

REGN Stock Latest News

Regeneron and Sanofi Terminate Real‑World Dupilumab Study in Chronic Urticaria
Company AnnouncementsRegeneron and Sanofi Terminate Real‑World Dupilumab Study in Chronic Urticaria
6h ago
SNY
REGN
Regeneron price target raised to $737 from $696 at RBC Capital
PremiumThe Fly
Regeneron price target raised to $737 from $696 at RBC Capital
8h ago
SNY
REGN
Regeneron price target raised to $758 from $730 at Morgan Stanley
PremiumThe Fly
Regeneron price target raised to $758 from $730 at Morgan Stanley
9h ago
REGN
Regeneron price target raised to $891 from $856 at BofA
PremiumThe Fly
Regeneron price target raised to $891 from $856 at BofA
9h ago
REGN
Regeneron price target raised to $795 from $750 at Cantor Fitzgerald
PremiumThe Fly
Regeneron price target raised to $795 from $750 at Cantor Fitzgerald
10h ago
REGN
Regeneron price target raised to $761 from $742 at Baird
PremiumThe FlyRegeneron price target raised to $761 from $742 at Baird
11h ago
REGN
Regeneron price target raised to $750 from $700 at Wells Fargo
Premium
The Fly
Regeneron price target raised to $750 from $700 at Wells Fargo
12h ago
REGN
Regeneron: Strong Execution, Growth Visibility and Pipeline Catalysts Drive Price Target Increase to $891
Premium
Ratings
Regeneron: Strong Execution, Growth Visibility and Pipeline Catalysts Drive Price Target Increase to $891
13h ago
REGN
Regeneron Earnings Call Highlights Dupixent-Driven Surge
PremiumCompany Announcements
Regeneron Earnings Call Highlights Dupixent-Driven Surge
22h ago
REGN
Regeneron cuts FY26 CapEx view to $1.03B-$1.1B from $1.1B-$1.2B
PremiumThe Fly
Regeneron cuts FY26 CapEx view to $1.03B-$1.1B from $1.1B-$1.2B
1d ago
REGN
Regeneron reports Q2 adjusted EPS $14.29, consensus $10.20
PremiumThe Fly
Regeneron reports Q2 adjusted EPS $14.29, consensus $10.20
1d ago
REGN
Regeneron Targets Safer Outpatient Myeloma Care With New Linvoseltamab Study
PremiumCompany Announcements
Regeneron Targets Safer Outpatient Myeloma Care With New Linvoseltamab Study
2d ago
REGN
Regeneron’s Mibavademab Study Completion Adds Quiet Upside in Rare Metabolic Disease
PremiumCompany AnnouncementsRegeneron’s Mibavademab Study Completion Adds Quiet Upside in Rare Metabolic Disease
2d ago
REGN
Regeneron Pharmaceuticals Lawsuit Alleges Investors Were Misled Before REGN Stock Drops 
Premium
Class Action
Regeneron Pharmaceuticals Lawsuit Alleges Investors Were Misled Before REGN Stock Drops 
3d ago
REGN
REGN Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
REGN Upcoming Earnings Report: What to Expect?
4d ago
REGN
Regeneron’s POTS Study Wraps Up: What REGN7544 Could Mean for REGN Investors
PremiumCompany Announcements
Regeneron’s POTS Study Wraps Up: What REGN7544 Could Mean for REGN Investors
10d ago
REGN
Regeneron price target raised to $1,000 from $995 at Guggenheim
PremiumThe Fly
Regeneron price target raised to $1,000 from $995 at Guggenheim
10d ago
REGN
Regeneron Pharmaceuticals Lawsuit Focuses on Trial Disclosures and REGN Stock Drops 
PremiumClass Action
Regeneron Pharmaceuticals Lawsuit Focuses on Trial Disclosures and REGN Stock Drops 
11d ago
REGN
Real-World Asthma Data on Dupixent: What Regeneron and Sanofi Investors Should Know
PremiumCompany Announcements
Real-World Asthma Data on Dupixent: What Regeneron and Sanofi Investors Should Know
11d ago
REGN
Biohaven enters into clinical supply agreement with Regeneron
PremiumThe FlyBiohaven enters into clinical supply agreement with Regeneron
11d ago
BHVN
REGN
Regeneron’s dupilumab granted orphan drug designation
Premium
The Fly
Regeneron’s dupilumab granted orphan drug designation
17d ago
REGN
Regeneron price target lowered to $856 from $860 at BofA
Premium
The Fly
Regeneron price target lowered to $856 from $860 at BofA
18d ago
REGN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >